Patents by Inventor Didier Hoarau
Didier Hoarau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414604Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: ApplicationFiled: April 28, 2023Publication date: December 28, 2023Applicant: Fresenius Kabi Deutschland GmbHInventors: Alain CUINE, Didier HOARAU, Pauline ROMAIN
-
Publication number: 20200345720Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: ApplicationFiled: March 18, 2020Publication date: November 5, 2020Applicant: Fresenius Kabi Deutschland GmbHInventors: Alain CUINE, Didier HOARAU, Pauline ROMAIN
-
Publication number: 20190167665Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: ApplicationFiled: February 11, 2019Publication date: June 6, 2019Applicant: Fresenius Kabi Deutschland GmbHInventors: Alain CUINE, Didier HOARAU, Pauline ROMAIN
-
Patent number: 10213424Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: GrantFiled: October 20, 2015Date of Patent: February 26, 2019Assignee: Fresenius Kabi Deutschland GmbHInventors: Alain Cuine, Didier Hoarau, Pauline Romain
-
Publication number: 20160175297Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: ApplicationFiled: October 20, 2015Publication date: June 23, 2016Inventors: Alain CUINE, Didier HOARAU, Pauline ROMAIN
-
Patent number: 9192608Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: GrantFiled: May 18, 2015Date of Patent: November 24, 2015Assignee: BECTON DICKINSON FRANCE S.A.S.Inventors: Alain Cuine, Didier Hoarau, Pauline Romain
-
Publication number: 20150246036Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: ApplicationFiled: May 18, 2015Publication date: September 3, 2015Inventors: Alain CUINE, Didier HOARAU, Pauline ROMAIN
-
Patent number: 9072781Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: GrantFiled: March 12, 2014Date of Patent: July 7, 2015Assignee: Becton, Dickinson France S.A.S.Inventors: Alain Cuine, Didier Hoarau, Pauline Romain
-
Publication number: 20140275144Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Becton Dickinson France S.A.S.Inventors: Alain CUINE, Didier Hoarau, Pauline Romain
-
Patent number: 8603525Abstract: An orally disintegrating multilayer tablet comprising at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and a pore-forming agent.Type: GrantFiled: July 31, 2007Date of Patent: December 10, 2013Assignee: EthypharmInventors: Pascal Oury, Catherine Herry, Didier Hoarau
-
Patent number: 8465776Abstract: The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.Type: GrantFiled: July 31, 2007Date of Patent: June 18, 2013Assignee: EthypharmInventor: Didier Hoarau
-
Publication number: 20090311320Abstract: This invention pertains to an orally disintegrating multilayer tablet wherein it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and optionally a pore-forming agent.Type: ApplicationFiled: July 31, 2007Publication date: December 17, 2009Applicant: ETHYPHARMInventors: Pascal Oury, Catherine Herry, Didier Hoarau
-
Publication number: 20090304792Abstract: The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.Type: ApplicationFiled: July 31, 2007Publication date: December 10, 2009Applicant: ETHYPHARMInventor: Didier Hoarau
-
Publication number: 20070141158Abstract: The invention relates to an amphiphilic heparin derivative formed from at least one type of partially N-desulfated heparin and at least one type of bile acid comprising one or several bile acid molecules grafted on a heparin molecule by an amide bond formed between the terminal carboxylic acid function of a bile acid and a primary heparin amine function which is initially present in the heparin or resulting from the N-desulfation. The inventive derivative is characterized in that the number of grafted bile acid molecules per 100 heparin disaccharide units ranges from 15 to 80 approximately.Type: ApplicationFiled: December 17, 2004Publication date: June 21, 2007Applicant: ETHYPHARMInventors: Didier Hoarau, Mahfoud Boustta, Christian Braud, Michel Vert
-
Publication number: 20050214378Abstract: The present invention relates to stealth lipid nanocapsules comprising an essentially lipid core which is liquid or semi-liquid at ambient temperature, and an outer lipid envelope comprising at least one hydrophilic surfactant which is lipidic in nature, at least one lipophilic surfactant which is lipidic in nature and at least one amphiphilic derivative of poly(ethylene glycol), the molar mass of the poly(ethylene glycol) component of which is greater than or equal to 1000 g/mol, preferably greater than or equal to 2000 g/mol, to the methods for the preparation thereof and to the use thereof as a carrier for active principle(s).Type: ApplicationFiled: June 11, 2003Publication date: September 29, 2005Applicant: ETHYPHARMInventors: Didier Hoarau, Pascal Delmas, Jean-Christophe Delmas
-
Publication number: 20040076683Abstract: The present invention relates to stealth lipid nanocapsules consisting of an essentially lipid core which is liquid or semi-liquid at ambient temperature, and an outer lipid envelope comprising at least one hydrophilic surfactant which is lipidic in nature, at least one lipophilic surfactant which is lipidic in nature and at least one amphiphilic derivative of poly(ethylene glycol), the molar mass of the poly(ethylene glycol) component of which is greater than or equal to 1 000 g/mol, preferably greater than or equal to 2 000 g/mol, to the methods for the preparation thereof and to the use thereof as a carrier for active principle(s).Type: ApplicationFiled: June 11, 2003Publication date: April 22, 2004Applicant: ETHYPHARMInventors: Didier Hoarau, Pascal Delmas, Jean-Christophe Leroux